Our Commitment

to Patients, Families and Providers

Our goal to support the health of patients and families goes beyond the therapeutics we provide. It extends to the education and support we develop in collaboration with health experts and advocates.

From disease awareness information to patient assistance to education and adherence support, our programs help empower patients and families to better understand and proactively manage their health.

Patient Assistance

We are committed to investing in patient assistance programs across our portfolio to help connect indicated patients and their healthcare providers to the information, resources and support they need to access our products and services in their time of need.

Makena Care Connection®

Our customer support center, Makena Care Connection, has established expertise in supporting patients by connecting eligible patients to a variety of support. This support includes:

Rx Support

Each woman is unique and so are her insurance benefit s. Because timely access is important we’ll aid in processing prescriptions, verifying insurance coverage, and obtaining prior authorizations (when applicable) to help patients get their prescription on time.

Financial Assistance

AMAG Pharmaceuticals is committed to helping ensure affordable access to Makena. We provide financial assistance to eligible commercially insured moms whose health plan covers Makena (to copays, coinsurance, and deductibles) and provide a free course of therapy

*Eligibility criteria include: Patient meets the FDA-approved indication (pregnant with a singleton with a history of singleton spontaneous preterm birth <37 weeks gestation).1In compliance with federal regulations, patients insured by government-funded programs (e.g., Medicaid, TRICARE, etc.) are not eligible. There are no upper-level income caps.

Home Injection by Healthcare Professionals

We can help coordinate Makena injections through a home health care organization. Once approved by insurance, moms prescribed Makena can choose to receive their injections by a healthcare professional in the comfort of their home or another location that’s convenient for them.

Education and Adherence

We understand that moms receiving Makena injections may need some encouragement and support to stick to their weekly injection schedule, and we want to help. This free service offers educational and adherence support to encourage women to make Makena part of their pregnancy and take an active role in their health.

AMAG Assist

We established AMAG Assist with the goal of helping to ensure that all indicated patients and their healthcare providers can obtain our therapies at the time of need. This reimbursement support program helps patients and providers understand the details of patient-specific health insurance coverage for our products and provides information on other sources of financial assistance for qualifying patients in need. More >

Newborn Possibilities Program®

For more than 20 years, the Newborn Possibilities Program has been supporting families with a qualifying medical need to help preserve their children’s newborn stem cells. By covering all costs for processing and storage for five years, the program enables a family and their healthcare provider to determine if a preserved stem cell unit could be used in future therapy. Over 6,000 families have enrolled in this program. More >

Patient Education and Support

We collaborate with recognized healthcare experts to develop education and support programs to empower patients and families to understand and proactively manage their health.

Growth You Can’t See

The Growth You Can’t See campaign supports and reinforces existing patient education by helping patients better understand their risks. For more information and resources, visit www.growthyoucantsee.com.

Family Health Registry™

We collect family health data through our CBR® Family Health Registry to help advance clinical understanding of disease and conditions that may be treatable with newborn stem cell therapy. More than 100,000 families have contributed data, with 15% of these families directly impacted by a condition that may one day benefit from regenerative medicine applications using newborn stem cells.1 More >


Reference: 1. Data on file, AMAG Pharmaceuticals, Inc.